Bringing almost 30 years of experience in the pharmaceutical and clinical trials industry, Tom Zoda, Ph.D. has joined Apex Innovative Sciences as Chief Operating Officer. In his role as COO, Dr. Zoda will work with the executive team to develop and implement strategies to grow Apex as a market leader in the Phase I-III clinical…
Read MorePosts by Clinical Trial Centers
Apex Innovative Sciences Appoints Brett A. English, Pharm.D., Ph.D., as Vice President of Scientific Affairs MARLTON, N.J. and GARDEN GROVE, Calif., April 8, 2021 — Apex Innovative Sciences (“Apex”), an industry-leading independent provider of clinical drug development and trial site services, today announced the appointment of Brett A. English, Pharm.D., Ph.D., as Vice President of…
Read MoreBioXcel Therapeutics, a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, will host a virtual Key Opinion Leader (“KOL”) event on Friday, February 19, 2021 from 11:00 am to 2:00 pm ET. The event aims to highlight BXCL501, the Company’s investigational, proprietary, orally dissolving thin film formulation of…
Read MoreLarry Ereshefsky, Pharm.D., Chief Scientific Officer of Apex Innovative Sciences, has published more than 130 peer-reviewed scholarly articles and abstracts. His latest work, “Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant,” has been published in the medical journal, Expert Review of Pharmacoeconomics & Outcomes…
Read MoreOur annual eCards are here and updated for 2021. Download the neuroscience-focused card as well as the general medical version. We’re excited to connect with you during these conferences. Virtual and Zoom meetings will keep us safer for now, and we’re hopeful that we’ll return to in-person conversations in the near future. Please check each…
Read MoreMARLTON, N.J. and GARDEN GROVE, Calif., Jan. 5, 2021 — Apex Innovative Sciences (Apex) and its affiliates are proud to announce their participation in three COVID-19 vaccine studies. With East and West Coast operations and six state-of-the-art clinical trial facilities, Apex is strongly positioned to pivot from its core central nervous system (CNS) business and…
Read MoreHoward Hassman, D.O., AOBFP discussed the formation of Apex Innovative Sciences, the COVID-19 vaccine studies conducted by Hassman Research Institute and CNS Research, and the use of psychedelics to treat a variety of disorders with Kevin Price, Host of The Price of Business Show. Listen to the interview in its entirety.
Read MoreNeurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced positive top-line results from the Phase 1 central nervous effects (CNS) clinical study of tolperisone. The study, utilizing a validated driving test, confirmed that tolperisone does not impair driving performance. In addition, tolperisone does not appear to cause sleepiness, a side…
Read MoreMarlton, N.J. and Garden Grove, Calif., Dec. 2, 2020 /PRNewswire/ — Since the emergence of the COVID-19 global pandemic, Apex Innovative Sciences (Apex) has distinguished itself as a leader in clinical trial continuity strategies. On the heels of FDA and CDC guidance in March 2020, Apex immediately instituted its COVID-19 Risk Mitigation and Response…
Read MoreApex Innovative Sciences has taken a leadership role in the industry with respect to researching strategies for managing the placebo and nocebo effects. A significant contribution toward this purpose is the development of the copyrighted Placebo-Control Reminder Script (PCRS) and its associated Daily No Expectation Reminder Magnet and Banner. The PCRS educates and reminds study…
Read More